SOVREMENNAYA PEDIATRIYA.2016.8(80):123-128; doi 10.15574/SP.2016.80.123 

Clinical possibilities of complex probiotic Probiz for the prevention of antibiotic-associated diarrhea and other intestinal inflammatory lesions (review)

Marushko Iu. V., Asonov A. O.

O.O. Bogomolets National Medical University, Kyiv, Ukraine

Аntibiotic-associated diarrhea is the primary potential negative effect of antibiotic therapy. Use of complex comprising a probiotic composition in a Saccharomyces boulardii, lactobacilli and bifidobacteria is an effective method of preventing and treating antibiotic-associated diarrhea and other intestinal inflammatory diseases in children.

Key words: diarrhea, Probiz, children.

References

1. Zakordonets LV, Kramarev SA, Beregovaya TV, Tolstanova AN. 2013. Antibiotik-assotsiirovanaya diareya: mehanizmyi razvitiya i vozmozhnosti korrektsii. Zdorove rebenka. 7(50): 69—73.

2. Zaharova IN, Mazankova LN et al. 2011. Antibiotik-assotsiirovannyie diarei u detey: problema i reshenie. Moskva: 48.

3. Zaharova IN, Berezhnaya IV, Dmitrieva YuA, Sugyan NG. 2015.Antibiotik-assotsiirovannyie diarei u detey: chto novogo? RMZh. 3: 128.

4. Grishel AI, Kishkurno EP. 2009. Probiotiki i ih rol v sovremennoy meditsine. Vestnik farmatsii. 1(43): 90—93.

5. Detskaya gastroenterologiya: rukovodstvo dlya vrachey. Pod red prof NP Shabalova. 2011. Moskva, MEDpress-inform: 736.

6. Zaplatnikov AL, Zaharova IN, Korovina NA. 2004. Clostridium difficile-infektsiya u detey. RMZh. 5: 373—377.

7. Zaharova IN, Mazankova LN, Dmitrieva YuA. 2009. Sovremennyie probiotiki dlya korrektsii mikrobiotsenoza kishechnika u detey. Voprosyi sovr pediatrii. 8; 2: 109—113.

8. Ivanko OG. 2014. Clinical aspects of antibiotic-associated diarrhea in children. Sovremennaya pediatriya. 2(58): 2—6.

9. Krivuschev BI. 2010. Disbakterioz i probiotiki. Zdorove rebenka. 3(24).

10. Fekety R, DuPont HL, Cooperstok M et al. 1996. Lechenie kolita, svyazannogo s priemom antibiotikov. Evropeyskoe rukovodstvo po klinicheskoy otsenke protivoinfektsionnyih lekarstvennyih sredstv. Pod red TR Beam. Per s angl. Pod red akad RAMN AG Chuchalina, prof LS Strachunskogo. Smolensk, Amipress: 302—306.

11. Maydannik VG. 2010. Antibiotik-assotsiirovannaya diareya, svyazannaya s Clostridium difficile. Zdorov'ya UkraYini: 20—22.

12. Maydannik VG. 2011. Antibiotiko-assotsiirovannaya diareya u detey. Kiev: 250.

13. Maydannik VG. 2013. Probiotiki: perspektivyi primeneniya v detskom vozdaste. Mezhdunarodnyiy zhurnal pediatrii, akusherstva i ginekologi. 4; 3.

14. Marushko YuV, Shef HH. 2007. Suchasnyi stan problemy antybiotykoasotsiiovanykh urazhen kyshechnyku u ditei. Perinatologiya i pediatriya. 4(32): 65-67.

15. Shevyakov MA. 2004. Antibiotik-assotsiirovannaya diareya i kandidoz kishechnika: vozmozhnosti lecheniya i profIlaktiki. Antibiotiki i himioterapiya. 49; 10: 26—29.

16. Scherbakov PL, Tsvetkov PM, Nechaeva LV. 2004. Antibiotik-assotsiirovannaya diareya u detey: osobennosti korrektsii mikrofloryi. Voprosyi sovr pediatrii. 3(2): 44—51.

17. Wickens K, Black P, Stanley TV et al. 2012. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 42: 1071—1079. https://doi.org/10.1111/j.1365-2222.2012.03975.x; PMid:22702506

18. Barbut F, Meynard JL. 2002. Managing antibiotic associated diarrhoea. BMJ. 324: 1345—1346. https://doi.org/10.1136/bmj.324.7350.1345; PMid:12052785 PMCid:PMC1123310

19. Bartlett JG. 2002. Antibiotic-associated diarrhea. N Engl J Med. 346; 5: 334—339. https://doi.org/10.1056/NEJMcp011603; PMid:11821511

20. Nylund CM, Goudie A, Garza JM et al. 2011. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med. 165: 451—457. PMID: 21199971; https://doi.org/10.1001/archpediatrics.2010.282.

21. Nyc O, Pituch H, Matejkova J et al. 2011. Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet. 377(9775): 1407. https://doi.org/10.1016/S0140-6736(11)60575-8

22. Curtin BF, Zarbalian Y, Flasar MH, von Rosenvinge E. 2013. Clostridium difficile-associated disease: Adherence with current guidelines at a tertiary medical center. World J Gastroenterol. 19(46): 8647—8651. https://doi.org/10.3748/wjg.v19.i46.8647; PMid:24379582 PMCid:PMC3870510

23. Johnson DA. 2013, May 31. difficile: Guidelines to Diagnose, Treat, and Prevent. http://www.medscape.com/viewarticle/804729_4.

24. David MS, Donald HA, Fabio B. 2003. Association Between Antibiotic Use and Primary Idiopathic Intussusception. Arch Pediatr Adolesc Med. Suppl 157(1): 54—59.

25. Delmee M. 2001. Laboratory diagnosis of Clostrydium difficile desease. Clin Microbiol Infect. 7(8): 411—416. https://doi.org/10.1046/j.1198-743x.2001.00294.x; PMid:11591203

26. Dinleyici EC, Eren M, Ozen M et al. 2012. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther. 12(4): 395—410. https://doi.org/10.1517/14712598.2012.664129; PMid:22335323

27. Kajander K, Krogius-Kurikka L, Rinttila T et al. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 26: 463—73. https://doi.org/10.1111/j.1365-2036.2007.03391.x; PMid:17635381

28. Sazawal S, Hiremath G, Dhingra U et al. 2006. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 6(6): 374—382. https://doi.org/10.1016/S1473-3099(06)70495-9

29. FAO/WAO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Argentina. 2001. http://www.fao.org/es/esn/Probio/report.pdf.

30. Feizizadeh S, Salehi-Abargouei A, Akbari V. 2014. Efficacy and Safety of Saccharomyces boulardii for Acute Diarrhea. Pediatrics. 134(1): 76—91. https://doi.org/10.1542/peds.2013-3950; PMid:24958586

31. Wistrom J, Norrby SR, Myhre EB et al. 2001. Frequency of antibioticassociated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 47(1): 43—50. https://doi.org/10.1093/jac/47.1.43; PMid:11152430

32. Marra AR, Edmond MB, Wenzel RP, Bearman GM. 2007. Hospitalacquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 7: 42; https://doi.org/10.1186/1471-2334-7-42; PMid:17517130 PMCid:PMC1888698.

33. Mercer M, Brinich MA, Geller G et al. 2012. How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol. 46: 138—144. https://doi.org/10.1097/MCG.0b013e318225f545; PMid:21716123 PMCid:PMC3202682

34. Lin HC, Lai CH, Lu JJ et al. 2011. Immunomodulatory effects of lactobacillus and Bifidobacterium on both murine and human mitogen-activated T cells. Int Arch Allergy Immunol. 156(2): 128—36. https://doi.org/10.1159/000322350; PMid:21576983

35. Doege K, Grajecki D, Zyriax BC et al. 2012. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood — a meta-analysis. Br J Nutr. 107: 1-6. https://doi.org/10.1017/S0007114511003400; PMid:21787448

36. Kligler B, Cohrssen A. 2008. Probiotics. Am Fam Physician. 78: 1073—1078. PMid:19007054

37. Lilly D, Stilwell RHM. 1965. Probiotics: growth promoting factors produced by microorganisms. Science. 147: 747—748. https://doi.org/10.1126/science.147.3659.747; PMid:14242024

38. McFarland LV. 2008. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3(5): 563—578. https://doi.org/10.2217/17460913.3.5.563; PMid:18811240

39. McFarland LV. 2007. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 5(2): 97—105. https://doi.org/10.1016/j.tmaid.2005.10.003; PMid:17298915

40. McFarland LV. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 16(18): 2202—2222. https://doi.org/10.3748/wjg.v16.i18.2202; PMid:20458757 PMCid:PMC2868213

41. Hogenauer C, Hammer HF, Krejs GJ, Reisinge EC. 1998. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 27: 702—710. https://doi.org/10.1086/514958; PMid:9798020

42. Nelsons Text Book of pediatrics. 19-th edition. 2011.

43. Hedge DD, Strain JD, Heins JR, Farver DK. 2008. New advances in the treatment of Clostridium difficile infection (CDI). Therapeutics and Clinical Risk Management. 4(5).

44. Kikuchi Y, Kunitoh-Asari A, Hayakawa K et al. 2014. Oral Administration of Lactobacillus plantarum Strain AYA Enhances IgA Secretion and Provides Survival Protection against Influenza Virus Infection in Mice. PLoS One. 9(1): e86416. https://doi.org/10.1371/journal.pone.0086416; PMid:24466081 PMCid:PMC3899257

45. Phavichitr N, Puwdee P, Tantibhaedhyangkul R. 2013.Cost-benefit analysis of the probiotic treatment of children hospitalized for acute diarrhea in Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 44(6): 1065—71. PMid:24450244

46. Lupse M, Flonta M, Cioara A et al. 2013. Predictors of First Recurrence in Clostridium dicile-Associated Disease. A Study of 306 Patients Hospitalized in a Romanian Tertiary Referral Center. J Gastrointestin Liver Dis Dec. 22; 4: 397—403.

47. LaRosa M, Bottaro G, Gulino N et al. 2003. Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructooligosaccharides in children: a multi-centric double-blind vs. placebo study. Minerva Pediatr. 55: 447—452.

48. Goldenberg JZ, Lytvyn L, Steurich J et al. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews. Issue 12. Art. No. CD004827. https://doi.org/10.1002/14651858.CD004827.pub4.

49. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. 2002. Probiotics in the prevention of antibiotic associated diarrhea: meta-analysis. BMJ. 324; 7350: 1361—1366. https://doi.org/10.1136/bmj.324.7350.1361; PMid:12052801 PMCid:PMC115209

50. Duman DG, Kumral ZN, Ercan F et al. 2013. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. Br J Nutr. 2: 1—7. https://doi.org/10.1017/s000711451200517x

51. Szajewska H, Guarino A, Hojsak I et al. 2014. Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. Behalf of the ESPGHAN Working Group for Probiotics and Prebiotics. JPGN. 58(4): 531—9. https://doi.org/10.1097/mpg.0000000000000320

52. Warren CA, Guerrant RL. 2011. Pathogenic C. difficile is here (and everywhere) to stay. Lancet. 377(9759): 8—9. https://doi.org/10.1016/S0140-6736(10)61885-5

53. Whelan K. 2011. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care. 14: 581-587. https://doi.org/10.1097/MCO.0b013e32834b8082; PMid:21892075

54. Wistrom J, Norrby SR, Myhre EB. 2001. Frequency of antibioticassociated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 47: 43—50. https://doi.org/10.1093/jac/47.1.43; PMid:11152430